Expression of High-mobility Group Box 1， Toll-like Receptor 4 in Epileptic Patients and Analysis of Their Influencing Factors
10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2021.0606
- VernacularTitle:癫痫患者血清高迁移率族蛋白1与TOLL样受体4的表达及影响因素
- Author:
Jia-ying YE
1
;
Lian-hong YANG
1
Author Information
1. Department of Neurology， SUN Yat-sen Memorial Hospital， SUN Yat-sen University， Guangzhou 510120， China
- Publication Type:Journal Article
- Keywords:
epilepsy;
high-mobility group box 1;
toll-like receptor 4;
intractable epilepsy
- From:
Journal of Sun Yat-sen University(Medical Sciences)
2021;42(6):839-845
- CountryChina
- Language:Chinese
-
Abstract:
PurposesTo explore the effect of HMGB1 and TLR4 in epilepsy as well as the influencing factors affecting the expression of HMGB1 and TLR4， we detected the levels of High-mobility group box 1（HMGB1） and Toll-like receptor 4 （TLR4） in serum of epileptic patients and analyzed their influencing factors. MethodsIn this prospective observational clinical research， a total of 72 patients who were diagnosed as primary epilepsy in our Hospital from September 2016 to September 2017 were selected as the experimental group and divided into three experimental subgroups： drug-resistant group （19 cases）， drug-effective group （32 cases） and unidentified group （21 cases）. A total of 43 healthy people in our hospital were selected as the control group. We collected 2 mL of blood from each person in the experimental group and the control group， and separated the serum from blood. The level of HMGB1 in serum was measured by flow fluorescence technology and the level of TLR4 in serum was measured by ELISA. Then， we analyzed the differences of the levels of serum HMGB1 and TLR4 among the experimental group， control group and experimental subgroups， the correlation between the levels of serum HMGB1 and TLR4 of the experimental group， as well as the correlation between the clinical influencing factors and HMGB1 and TLR4. ResultsThe levels of serum HMGB1 and TLR4 in the experimental group were （370±211） pg/mL and （36.0±3.8） ng/mL， which were significantly higher than （284±158） pg/mL and （34.4±4.1） ng/mL in the control group； and those in the drug-resistant group were （498±214） pg/mL and （38.4±3.2） ng/mL， which were significantly higher than （301±182） pg/mL and （34.5±3.8） ng/mL in the drug-effective group （P < 0.05）. There was a positive linear correlation between HMGB1 and TLR4 in the experimental group （R2=0.479）. The level of serum HMGB1 in the experimental group was related to seizure frequency （F=6.71， P=0.012）， the duration of disease （F=6.55， P=0.013） and drug reactivity （F=3.96， P=0.024）. The level of serum TLR4 in the experimental group was related to seizure frequency （F=4.68， P=0.034） and drug reactivity （F=3.80， P=0.027）. ConclusionsThe levels of serum HMGB1 and TLR4 in epileptic patients are higher than those of non-epileptic patients. The levels of serum HMGB1 and TLR4 in patients with intractable epilepsy （IE） are higher than those in patients with non-intractable epilepsy. There is a positive correlation between HMGB1 and TLR4. The level of serum HMGB1 in epileptic patients is related to seizure frequency， the duration of disease and drug reactivity. The level of serum TLR4 in epileptic patients is related to seizure frequency and drug reactivity.
